Table 2.
BBIBP-CorV vaccine adverse events and post-vaccination MS activity
| Variable | Level | Total cohort (N = 209) |
|---|---|---|
| Non-serious adverse events † | yes | 138 (66.0) |
| fever (< 40°c) | 43 (20.6) | |
| injection site pain | 36 (17.2) | |
| fatigue/malaise | 34 (16.3) | |
| headache | 34 (16.3) | |
| myalgia | 24 (11.5) | |
| chill | 17 (8.1) | |
| anorexia | 8 (3.8) | |
| nausea/vomiting | 7 (3.4) | |
| arthralgia | 4 (1.9) | |
| dizziness | 4 (1.9) | |
| vertigo | 3 (1.4) | |
| nasal congestion/sore throat | 2 (1.0) | |
| Serious adverse events ‡ | yes | 0 |
| MS activity ≤ 12 w of vaccination | yes | 14 (6.7) |
| between V1 and V2 | 3 (1.4) | |
| after V2 | 11 (5.3) | |
| < 6 weeks | 10 (4.8) | |
| 6–12 weeks | 4 (1.9) |
Note: The frequency (%) was used to describe categorical data. Abbreviations: MS: multiple sclerosis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; V1: 1st dose of vaccine; V2: 2nd dose of vaccine
† Each participant might have reported multiple adverse events following vaccination
‡ Serious adverse events were defined as anaphylaxis, thrombosis with thrombocytopenia syndrome, Guillain–Barré syndrome, myocarditis, pericarditis, and events requiring hospital admission (except for MS disease activity, which was separately evaluated)